These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 8118648)
41. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541 [TBL] [Abstract][Full Text] [Related]
42. Role of lung injury in the pathogenesis of hyaline membrane disease in premature baboons. Meredith KS; deLemos RA; Coalson JJ; King RJ; Gerstmann DR; Kumar R; Kuehl TJ; Winter DC; Taylor A; Clark RH J Appl Physiol (1985); 1989 May; 66(5):2150-8. PubMed ID: 2745284 [TBL] [Abstract][Full Text] [Related]
43. Bispecific monoclonal antibodies increase the fibrin-specific fibrinolytic activity of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). Bos R; Nieuwenhuizen W Ann N Y Acad Sci; 1992 Dec; 667():428-30. PubMed ID: 1309066 [No Abstract] [Full Text] [Related]
44. Priming for enhanced alveolar fibrin deposition after hemorrhagic shock: role of tumor necrosis factor. Fan J; Kapus A; Li YH; Rizoli S; Marshall JC; Rotstein OD Am J Respir Cell Mol Biol; 2000 Apr; 22(4):412-21. PubMed ID: 10745022 [TBL] [Abstract][Full Text] [Related]
45. The fibrinolytic enzyme defect of hyaline membrane disease. LIEBERMAN J; KELLOGG F Calif Med; 1961 Nov; 95(5):278-82. PubMed ID: 14465183 [TBL] [Abstract][Full Text] [Related]
46. Biochemical, clinical, and morphologic studies on lungs of infants with bronchopulmonary dysplasia. Cherukupalli K; Larson JE; Rotschild A; Thurlbeck WM Pediatr Pulmonol; 1996 Oct; 22(4):215-29. PubMed ID: 8905882 [TBL] [Abstract][Full Text] [Related]
47. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus. Glas-Greenwalt P; Kant KS; Allen C; Pollak VE J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000 [TBL] [Abstract][Full Text] [Related]
48. The expression of plasminogen activator system in a rat model of periodontal wound healing. Xiao Y; Li H; Bunn C; Bartold PM J Periodontol; 2001 Jul; 72(7):849-57. PubMed ID: 11495131 [TBL] [Abstract][Full Text] [Related]
49. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Matsuo O; Rijken DC; Collen D Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339 [TBL] [Abstract][Full Text] [Related]
50. Inhaled unfractionated heparin improves abnormalities of alveolar coagulation, fibrinolysis and inflammation in endotoxemia-induced lung injury rats. Wang ZY; Wu SN; Zhu ZZ; Yang BX; Zhu X Chin Med J (Engl); 2013 Jan; 126(2):318-24. PubMed ID: 23324284 [TBL] [Abstract][Full Text] [Related]
51. Pseudomonas aeruginosa toxin ExoU induces a PAF-dependent impairment of alveolar fibrin turnover secondary to enhanced activation of coagulation and increased expression of plasminogen activator inhibitor-1 in the course of mice pneumosepsis. Machado GB; de Oliveira AV; Saliba AM; de Lima CD; Suassuna JH; Plotkowski MC Respir Res; 2011 Aug; 12(1):104. PubMed ID: 21819560 [TBL] [Abstract][Full Text] [Related]
52. Bronchopulmonary dysplasia impairs L-type amino acid transporter-1 expression in human and baboon lung. Bao EL; Chystsiakova A; Brahmajothi MV; Sunday ME; Pavlisko EN; Wempe MF; Auten RL Pediatr Pulmonol; 2016 Oct; 51(10):1048-1056. PubMed ID: 26918397 [TBL] [Abstract][Full Text] [Related]
53. Cytokine response during hyperoxia: sequential production of pulmonary tumor necrosis factor and interleukin-6 in neonatal rats. Ben-Ari J; Makhoul IR; Dorio RJ; Buckley S; Warburton D; Walker SM Isr Med Assoc J; 2000 May; 2(5):365-9. PubMed ID: 10892391 [TBL] [Abstract][Full Text] [Related]
54. Plasminogen-dependent and -independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes. Lijnen HR; Wagner EF; Collen D Thromb Haemost; 1997 Feb; 77(2):362-7. PubMed ID: 9157597 [TBL] [Abstract][Full Text] [Related]
55. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase. Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163 [TBL] [Abstract][Full Text] [Related]
56. Deficiencies in lung surfactant proteins A and D are associated with lung infection in very premature neonatal baboons. Awasthi S; Coalson JJ; Yoder BA; Crouch E; King RJ Am J Respir Crit Care Med; 2001 Feb; 163(2):389-97. PubMed ID: 11179112 [TBL] [Abstract][Full Text] [Related]
57. Pulmonary toxicity of deferoxamine in iron-poisoned mice. Adamson IY; Sienko A; Tenenbein M Toxicol Appl Pharmacol; 1993 May; 120(1):13-9. PubMed ID: 8511775 [TBL] [Abstract][Full Text] [Related]
58. [Expression of TGF-β1 and PAI-1 in premature infants with bronchopulmonary dysplasia]. Zhang JF; Hunag RZ; Huang GF; Ou WM; Li JF; Chen JJ Zhongguo Dang Dai Er Ke Za Zhi; 2014 Aug; 16(8):810-3. PubMed ID: 25140773 [TBL] [Abstract][Full Text] [Related]
59. Bronchoalveolar lavage procoagulant activity in bleomycin-induced lung injury in marmosets. Characterization and relationship to fibrin deposition and fibrosis. Idell S; Gonzalez KK; MacArthur CK; Gillies C; Walsh PN; McLarty J; Thrall RS Am Rev Respir Dis; 1987 Jul; 136(1):124-33. PubMed ID: 2440356 [TBL] [Abstract][Full Text] [Related]
60. Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Chapman HA; Allen CL; Stone OL Am Rev Respir Dis; 1986 Mar; 133(3):437-43. PubMed ID: 3954252 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]